How Managed Access Programs Really Work: The Role of BAP Pharma Behind the Scenes
From the outside, a Managed Access Program can look deceptively simple. A patient needs treatment. A physician makes a request. Medicine is supplied. In reality, every successful access program is supported by a complex network of people, processes, and decisions working quietly in the background. This is why pharmaceutical and biotech companies partner with BAP […]
The Rare Disease Access Gap – Why Operational Readiness is Becoming the New Barrier to Treatment
For years, Rare Disease Access has been defined by three critical questions: Does a treatment exist? Is it approved? Will it be funded? Today, those questions remain important, but they no longer tell the whole story. Advances in genomics, new-born screening and rare disease regulation are enabling patients to be identified earlier than ever before. […]
Faster IND Timelines Don’t Reduce Complexity, They Shift It
Across the life sciences industry, there is growing pressure to accelerate the path from development to patient access. Faster IND approvals, streamlined pathways and reduced regulatory timelines are helping sponsors move programmes forward at unprecedented speed. However, there is an important reality that often goes unspoken: Speed at the regulatory level does not eliminate complexity. […]